Aptorum Group Limited (NASDAQ: APM)
$0.7830
+0.0438 ( +8.00% ) 11.5K
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Market Data
Open
$0.7830
Previous close
$0.7393
Volume
11.5K
Market cap
$4.15M
Day range
$0.7150 - $0.7720
52 week range
$0.4600 - $17.4900
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Form 6-K | 87 | Dec 20, 2024 |
6-k | Form 6-K | 1 | Dec 11, 2024 |
6-k | Form 6-K | 5 | Nov 08, 2024 |
6-k | Form 6-K | 1 | Nov 01, 2024 |
6-k/a | Form 6-K | 2 | Oct 25, 2024 |
6-k | Form 6-K | 3 | Aug 09, 2024 |
6-k | Form 6-K | 2 | May 31, 2024 |
6-k | Form 6-K | 3 | Apr 30, 2024 |
20-f | Annual reports | 126 | Apr 30, 2024 |
6-k | Form 6-K | 6 | Mar 06, 2024 |